{
    "clinical_study": {
        "@rank": "102648", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "6 times daily"
            }, 
            {
                "arm_group_label": "2% Rebamipide liquid", 
                "arm_group_type": "Experimental", 
                "description": "6 times daily"
            }, 
            {
                "arm_group_label": "4% Rebamipide liquid", 
                "arm_group_type": "Experimental", 
                "description": "6 times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the efficacy and safety of rebamipide liquid for chemoradiotherapy-induced\n      oral mucositis in patients with head and neck cancer following administration of rebamipide\n      and to determine the optimal dose of rebamipide."
        }, 
        "brief_title": "A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Head and Neck Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Head and Neck Neoplasms", 
                "Stomatitis", 
                "Mucositis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Head and neck cancer patients scheduled for definitive or postoperative\n             chemoradiotherapy.\n\n          -  Patients with a histopathological diagnosis of head and neck cancer and primary tumor\n             in one of the following regions.\n\n               1. Definitive therapy: nasopharynx, oropharynx, hypopharynx, or larynx\n\n               2. Postoperative therapy: oral cavity, ropharynx, hypopharynx, or larynx\n\n          -  Patients with no history of chemotherapy, radiotherapy, or chemoradiotherapy for head\n             and neck cancer\n\n          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status score\n             of 0 or 1\n\n          -  Patients who are able to hold fluid in the mouth\n\n          -  Patients who are able to swallow the investigational medicinal product (IMP)\n\n          -  Patients expected to survive for at least 3 months\n\n          -  Patients who have given written informed consent in person\n\n          -  Patients who can stay at or visit the hospital for scheduled examinations and\n             observations\n\n          -  Patients who are able to take contraceptive measures to avoid pregnancy of the\n             patient or their partner from the time of informed consent until 4 weeks after\n             completion of IMP administration\n\n        Exclusion Criteria:\n\n          -  Patients with primary malignant tumors other than head and neck cancer.\n\n          -  Patients with symptomatic viral, bacterial, or fungal infection\n\n          -  Patients with serious renal impairment\n\n          -  Patients with distant metastasis\n\n          -  Patients with severe complications (uncontrolled cardiac disease, diabetes,\n             hypertension, etc)\n\n          -  Patients with any of the following laboratory test results:\n\n               1. Neutrophil count: <1500 L\n\n               2. Platelet count: <75000 L\n\n               3. Hemoglobin: <10.0 g/L\n\n               4. Aspartate aminotransferase (AST): >3 times the upper limit of the reference\n                  value at the trial site\n\n               5. Alanine aminotransferase (ALT): >3 times the upper limit of the reference value\n                  at the trial site\n\n               6. Serum bilirubin: >1.5 times the upper limit of the reference value at the trial\n                  site\n\n               7. Serum albumin: <3.0 g/dL\n\n               8. Serum creatinine: >1.5 the upper limit of the reference value at the trial site\n\n               9. Creatinine clearance : <30 mL/min\n\n          -  Patients complicated with autoimmune disease\n\n          -  Patients requiring continuous systemic administration of glucocorticoid\n\n          -  Female patients who are pregnant or lactating, who may possibly be pregnant, or who\n             wish to become pregnant\n\n          -  Patients who have participated in any other clinical trial within 4 weeks prior to\n             initiation of chemoradiotherapy\n\n          -  Patients who have a history of drug allergy to rebamipide, cisplatin, or other\n             platinum compounds\n\n          -  Patients who are otherwise judged by the investigator or sub-investigator to be\n             inappropriate for inclusion in the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085460", 
            "org_study_id": "037-12-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2% Rebamipide liquid", 
                "intervention_name": "2% Rebamipide liquid", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "4% Rebamipide liquid", 
                "intervention_name": "4% Rebamipide liquid", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Rebamipide"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kinki Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tohoku Region", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer", 
        "overall_contact": {
            "last_name": "Drug Information Center", 
            "phone": "+81-3-6361-7314"
        }, 
        "overall_official": {
            "affiliation": "Otsuka Pharmaceutical Co., Ltd.", 
            "last_name": "Jun-ichi Hashimoto, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of oral mucositis graded as severe or worse.", 
            "safety_issue": "No", 
            "time_frame": "77 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085460"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Onset time, duration and incidence of oral mucositis.", 
                "safety_issue": "No", 
                "time_frame": "77 days"
            }, 
            {
                "measure": "The maximum severity grade for oral mucositis.", 
                "safety_issue": "No", 
                "time_frame": "77 days"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "77 days"
            }
        ], 
        "source": "Otsuka Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}